Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

N. G. McElvaney, B. Doujaiji, M. J. Moan, M. R. Burnham, M. C. Wu, Ronald Crystal

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Recombinant secretory leukoprotease inhibitor (rSLPI), a recombinant form of a natural airway inhibitor of neutrophil elastase (NE), is a potential therapeutic agent for cystic fibrosis (CF), a condition characterized by airway derangement mediated in part by the large burden of NE on the CF respiratory epithelial surface. After in vitro studies that demonstrated that aerosolized rSLPI retains its form and function, rSLPI was administered via aerosol to normal individuals and individuals with CF to determine the pharmacokinetics of in vivo rSLPI augmentation of the anti-NE defenses of the respiratory epithelial surface. After rSLPI aerosolization to normal individuals (100 mg single dose or 100 mg twice daily for 1 wk) there was a marked increase in SLPI levels and anti-NE capacity in airway epithelial lining fluid (ELF) at 1 h, diminishing gradually over 4 to 12 h. Interestingly, the ELF SLPI levels and anti-NE capacity achieved 12 h after 1 wk of rSLPI aerosols were no different than those 12 h after a single dose of rSLPI, suggesting that rSLPI does not accumulate on the respiratory epithelial surface after aerosolization. The ability of rSLPI to suppress NE in vivo was evaluated by aerosolization of rSLPI to individuals with CF, first as an escalating dose to assess safety, and then at doses of 100 mg twice daily for 1 wk or 50 mg twice daily for 2 wk. Before aerosol, SLPI levels in ELF of individuals with CF were the same as in normal individuals, but unlike normal individuals, individuals with CF had active NE in ELF (12.4 ± 3.0 μM) indicating that the SLPI in CF ELF was inactive. After aerosolization of 100 mg rSLPI twice daily for 1 wk there was a reduction in ELF active NE. In contrast, ELF active NE levels were not reduced with 50 mg twice daily, likely due to the failure of this dose regime to sufficiently elevate ELF SLPI levels. These data show that rSLPI is functional after both in vitro and in vivo aerosolization and can significantly suppress the NE burden in the CF lung but must be given regularly and in sufficient quantity to be effective.

Original languageEnglish
Pages (from-to)1056-1060
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume148
Issue number4
DOIs
Publication statusPublished - 1 Jan 1993
Externally publishedYes

Fingerprint

Secretory Leukocyte Peptidase Inhibitor
Cystic Fibrosis
Leukocyte Elastase
Pharmacokinetics
Aerosols
Secretory Proteinase Inhibitory Proteins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. / McElvaney, N. G.; Doujaiji, B.; Moan, M. J.; Burnham, M. R.; Wu, M. C.; Crystal, Ronald.

In: American Review of Respiratory Disease, Vol. 148, No. 4, 01.01.1993, p. 1056-1060.

Research output: Contribution to journalArticle

McElvaney, N. G. ; Doujaiji, B. ; Moan, M. J. ; Burnham, M. R. ; Wu, M. C. ; Crystal, Ronald. / Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. In: American Review of Respiratory Disease. 1993 ; Vol. 148, No. 4. pp. 1056-1060.
@article{c12c40d7733945f0a3891a895d667515,
title = "Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis",
abstract = "Recombinant secretory leukoprotease inhibitor (rSLPI), a recombinant form of a natural airway inhibitor of neutrophil elastase (NE), is a potential therapeutic agent for cystic fibrosis (CF), a condition characterized by airway derangement mediated in part by the large burden of NE on the CF respiratory epithelial surface. After in vitro studies that demonstrated that aerosolized rSLPI retains its form and function, rSLPI was administered via aerosol to normal individuals and individuals with CF to determine the pharmacokinetics of in vivo rSLPI augmentation of the anti-NE defenses of the respiratory epithelial surface. After rSLPI aerosolization to normal individuals (100 mg single dose or 100 mg twice daily for 1 wk) there was a marked increase in SLPI levels and anti-NE capacity in airway epithelial lining fluid (ELF) at 1 h, diminishing gradually over 4 to 12 h. Interestingly, the ELF SLPI levels and anti-NE capacity achieved 12 h after 1 wk of rSLPI aerosols were no different than those 12 h after a single dose of rSLPI, suggesting that rSLPI does not accumulate on the respiratory epithelial surface after aerosolization. The ability of rSLPI to suppress NE in vivo was evaluated by aerosolization of rSLPI to individuals with CF, first as an escalating dose to assess safety, and then at doses of 100 mg twice daily for 1 wk or 50 mg twice daily for 2 wk. Before aerosol, SLPI levels in ELF of individuals with CF were the same as in normal individuals, but unlike normal individuals, individuals with CF had active NE in ELF (12.4 ± 3.0 μM) indicating that the SLPI in CF ELF was inactive. After aerosolization of 100 mg rSLPI twice daily for 1 wk there was a reduction in ELF active NE. In contrast, ELF active NE levels were not reduced with 50 mg twice daily, likely due to the failure of this dose regime to sufficiently elevate ELF SLPI levels. These data show that rSLPI is functional after both in vitro and in vivo aerosolization and can significantly suppress the NE burden in the CF lung but must be given regularly and in sufficient quantity to be effective.",
author = "McElvaney, {N. G.} and B. Doujaiji and Moan, {M. J.} and Burnham, {M. R.} and Wu, {M. C.} and Ronald Crystal",
year = "1993",
month = "1",
day = "1",
doi = "10.1164/ajrccm/148.4_Pt_1.1056",
language = "English",
volume = "148",
pages = "1056--1060",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

AU - McElvaney, N. G.

AU - Doujaiji, B.

AU - Moan, M. J.

AU - Burnham, M. R.

AU - Wu, M. C.

AU - Crystal, Ronald

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Recombinant secretory leukoprotease inhibitor (rSLPI), a recombinant form of a natural airway inhibitor of neutrophil elastase (NE), is a potential therapeutic agent for cystic fibrosis (CF), a condition characterized by airway derangement mediated in part by the large burden of NE on the CF respiratory epithelial surface. After in vitro studies that demonstrated that aerosolized rSLPI retains its form and function, rSLPI was administered via aerosol to normal individuals and individuals with CF to determine the pharmacokinetics of in vivo rSLPI augmentation of the anti-NE defenses of the respiratory epithelial surface. After rSLPI aerosolization to normal individuals (100 mg single dose or 100 mg twice daily for 1 wk) there was a marked increase in SLPI levels and anti-NE capacity in airway epithelial lining fluid (ELF) at 1 h, diminishing gradually over 4 to 12 h. Interestingly, the ELF SLPI levels and anti-NE capacity achieved 12 h after 1 wk of rSLPI aerosols were no different than those 12 h after a single dose of rSLPI, suggesting that rSLPI does not accumulate on the respiratory epithelial surface after aerosolization. The ability of rSLPI to suppress NE in vivo was evaluated by aerosolization of rSLPI to individuals with CF, first as an escalating dose to assess safety, and then at doses of 100 mg twice daily for 1 wk or 50 mg twice daily for 2 wk. Before aerosol, SLPI levels in ELF of individuals with CF were the same as in normal individuals, but unlike normal individuals, individuals with CF had active NE in ELF (12.4 ± 3.0 μM) indicating that the SLPI in CF ELF was inactive. After aerosolization of 100 mg rSLPI twice daily for 1 wk there was a reduction in ELF active NE. In contrast, ELF active NE levels were not reduced with 50 mg twice daily, likely due to the failure of this dose regime to sufficiently elevate ELF SLPI levels. These data show that rSLPI is functional after both in vitro and in vivo aerosolization and can significantly suppress the NE burden in the CF lung but must be given regularly and in sufficient quantity to be effective.

AB - Recombinant secretory leukoprotease inhibitor (rSLPI), a recombinant form of a natural airway inhibitor of neutrophil elastase (NE), is a potential therapeutic agent for cystic fibrosis (CF), a condition characterized by airway derangement mediated in part by the large burden of NE on the CF respiratory epithelial surface. After in vitro studies that demonstrated that aerosolized rSLPI retains its form and function, rSLPI was administered via aerosol to normal individuals and individuals with CF to determine the pharmacokinetics of in vivo rSLPI augmentation of the anti-NE defenses of the respiratory epithelial surface. After rSLPI aerosolization to normal individuals (100 mg single dose or 100 mg twice daily for 1 wk) there was a marked increase in SLPI levels and anti-NE capacity in airway epithelial lining fluid (ELF) at 1 h, diminishing gradually over 4 to 12 h. Interestingly, the ELF SLPI levels and anti-NE capacity achieved 12 h after 1 wk of rSLPI aerosols were no different than those 12 h after a single dose of rSLPI, suggesting that rSLPI does not accumulate on the respiratory epithelial surface after aerosolization. The ability of rSLPI to suppress NE in vivo was evaluated by aerosolization of rSLPI to individuals with CF, first as an escalating dose to assess safety, and then at doses of 100 mg twice daily for 1 wk or 50 mg twice daily for 2 wk. Before aerosol, SLPI levels in ELF of individuals with CF were the same as in normal individuals, but unlike normal individuals, individuals with CF had active NE in ELF (12.4 ± 3.0 μM) indicating that the SLPI in CF ELF was inactive. After aerosolization of 100 mg rSLPI twice daily for 1 wk there was a reduction in ELF active NE. In contrast, ELF active NE levels were not reduced with 50 mg twice daily, likely due to the failure of this dose regime to sufficiently elevate ELF SLPI levels. These data show that rSLPI is functional after both in vitro and in vivo aerosolization and can significantly suppress the NE burden in the CF lung but must be given regularly and in sufficient quantity to be effective.

UR - http://www.scopus.com/inward/record.url?scp=0027495712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027495712&partnerID=8YFLogxK

U2 - 10.1164/ajrccm/148.4_Pt_1.1056

DO - 10.1164/ajrccm/148.4_Pt_1.1056

M3 - Article

VL - 148

SP - 1056

EP - 1060

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4

ER -